Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Oral Nanatinostat (Nstat) and Valganciclovir (VGCV) in Patients with Recurrent Epstein-Barr Virus (EBV)-Positive Lymphomas: Initial Phase 2 Results

Pierluigi Porcu, MD, Bradley Haverkos, MD MPH, MS, Onder Alpdogan, MD, Robert Baiocchi, MD PhD, Jonathan E Brammer, MD, Tatyana A. Feldman, MD, Marcelo Capra, MD PhD, Elizabeth A Brem, MD, Phillip Scheinberg, MD, Juliana Pereira, MD PhD, Leyla Shune, MD, Afton Katkov, MSc, Robert McRae, Lisa Rojkjaer, MD, Ivor Royston, MD, Douglas V. Faller, MD PhD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-140843

Published: 2020

Journal Articles

Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refractory (R/R) Epstein-Barr Virus (EBV)-Positive B-Cell, T-Cell, and Hodgkin Lymphoma: Interim Safety and Efficacy Results from a Phase 1b/2a Study

Blood (2019) 134 (Supplement_1): 465.

https://doi.org/10.1182/blood-2019-132004

Published: 2019

Journal Articles

Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)

Angela Dispenzieri, MD, Eftathios Kastritis, Ashutosh D Wechalekar, MB BS, MD FRCP, FRCPath, DM, Stefan O. Schönland, MD, Kihyun Kim, MD, Vaishali Sanchorawala, MD, Heather J Landau, MD, Fiona Kwok, FRACP,FRCPA,MBBS, Kenshi Suzuki, MD PhD, Raymond L Comenzo, MD, Deborah Berg, RN, MSN, Guohui Liu, PhD, Douglas V. Faller, MD PhD, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 139.

https://doi.org/10.1182/blood-2019-124409

Published: 2019

Journal Articles

Patient-Centered Evaluation of Clinical Benefit in Acute Myeloid Leukemia: Importance of Early Engagement with Patients

Jill A. Bell, PhD MS, Farrah Anne Pompilus, MA, Alissa Rams, BA, Yanyan Zhu, PhD MPH, Anna Ciesluk, MPH, Rafael Bejar, MD PhD, Robert J. Fram, MD, Douglas V. Faller, MD PhD, Patrick Marquis, MD MBA

Blood (2019) 134 (Supplement_1): 5898.

https://doi.org/10.1182/blood-2019-128517

Published: 2019

Journal Articles

Assessing Patient-Reported Outcomes in People with Myelodysplastic Syndromes: Can a Customized Selection of Items from the EORTC Library Enhance the EORTC QLQ-C30?

Jill A Bell, PhD, Farrah A Pompilus, Anna Christian, MPH, Flora Mazerolle, MSc, Fatima Scipione, Rafael Bejar, MD PhD, Aaron Galaznik, PhD, Robert J. Fram, MD, Douglas V. Faller, MD PhD, Stefan Cano, PhD CPsychol, AFBPsS, Antoine Regnault, PhD

Blood (2018) 132 (Supplement 1): 4856.

https://doi.org/10.1182/blood-2018-99-116977

Published: 2018

Journal Articles

Patient Perspectives on Symptom Experience and Impact on Health-Related Quality of Life in Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia

Jill A Bell, PhD, Aaron Galaznik, MD, Farrah A Pompilus, Sara Strzok, Robert J. Fram, MD, Douglas V. Faller, MD PhD, Patrick Marquis

Blood (2017) 130 (Supplement 1): 3458.

https://doi.org/10.1182/blood.V130.Suppl_1.3458.3458

Published: 2017

Journal Articles

Healthcare Costs in Elderly Patients with Acute Myeloid Leukemia (AML) in Routine Clinical Care in the United States (US)

Jill A Bell, PhD, Aaron Galaznik, MD, Sharanya Murty, PhD, Megan Pollack, PharmD, Augustina Ogbonnaya, MPH, Michael T. Eaddy, PharmD, PhD, Robert J. Fram, MD, Douglas V. Faller, MD PhD, Vamsi Kota, MBBS

Blood (2017) 130 (Supplement 1): 3459.

https://doi.org/10.1182/blood.V130.Suppl_1.3459.3459

Published: 2017

Journal Articles

Enhancing the Content of the EORTC QLQ-C30 to Maximize the Detection of Treatment Benefit in Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myeloid Leukemia Using the EORTC Item Bank

Jill A Bell, PhD, Aaron Galaznik, MD, Farrah A Pompilus, Sara Strzok, Rafael Bejar, MD PhD, Robert J. Fram, MD, Douglas V. Faller, MD PhD, Patrick Marquis

Blood (2017) 130 (Supplement 1): 3457.

https://doi.org/10.1182/blood.V130.Suppl_1.3457.3457

Published: 2017

Journal Articles

Treatment Characteristics and Outcomes for Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia (AML) Treated in the United States with Either 7+3 or a Hypomethylating Agent (HMA)

Jill A Bell, PhD, Aaron Galaznik, MD, Eileen Farrelly, MPH, Sharanya Murty, PhD, Augustina Ogbonnaya, MPH, Michael T. Eaddy, PharmD, PhD, Robert J. Fram, MD, Douglas V. Faller, MD PhD, Vamsi Kota, MBBS

Blood (2017) 130 (Supplement 1): 2167.

https://doi.org/10.1182/blood.V130.Suppl_1.2167.2167

Published: 2017

Journal Articles

Multiple Oral Therapeutics Suppress Repressors (LSD-1, HDACs, and BCL11A) of Gamma Globin Gene Expression

Yan Dai, PhD, Douglas V Faller, MD PhD, Jose I Sangerman, PhD, Suthat Fucharoen, Susan P Perrine, MD

Blood (2014) 124 (21): 2687.

https://doi.org/10.1182/blood.V124.21.2687.2687

Published: 2014

Journal Articles

Next Generation Clinical-Stage HbF Inducers Exhibit Multiple Molecular Actions In Vitro and In Vivo and Offer Personalized Therapeutic Regimens

Betty S. Pace, MD, Jose I Sangerman, PhD, Michael S Boosalis, PhD, Roman Wolf, DVM, Yan Dai, PhD, David H.K. Chui, MD, Levi Makala, PhD, DVM, Biadru Li, PhD, Douglas V Faller, MD, PhD, Susan P Perrine, MD

Blood (2013) 122 (21): 560.

https://doi.org/10.1182/blood.V122.21.560.560

Published: 2013

Journal Articles

An Approach for Tailoring Diverse Therapeutic Inducers of Fetal Globin to Genetic Modifier Profiles,

Susan P Perrine, MD, David H.K. Chui, MD, Jose I Sangerman, PhD, Michael S Boosalis, PhD, Douglas V Faller, MD, PhD

Blood (2011) 118 (21): 3188.

https://doi.org/10.1182/blood.V118.21.3188.3188

Published: 2011

Journal Articles

Identification of New and Diverse Inducers of Fetal Hemoglobin with High Throughput Screening (HTS)

Jose I Sangerman, PhD, Michael S Boosalis, PhD, Ling Shen, MD, Sarah Haigh, PhD, Ada Kane, Gary L White, DVM, MMS, Susan P Perrine, MD, Douglas V Faller, MD, PhD

Blood (2010) 116 (21): 4277.

https://doi.org/10.1182/blood.V116.21.4277.4277

Published: 2010

Journal Articles

Short-Term Exposure to Arginine Butyrate, in Combination with Ganciclovir, Is as Effective as Continuous Exposure for Virus-Targeted Therapy of EBV-Positive Lymphomas.

Douglas V Faller, MD, PhD, Sajal Ghosh, PhD, Tatyana Feldman, MD, Adam Lerner, MD, Judith Smith, RN, Andre Goy, MD, Ronald Berenson, MD, Susan Perrine, MD

Blood (2009) 114 (22): 4754.

https://doi.org/10.1182/blood.V114.22.4754.4754

Published: 2009

Journal Articles

HQK-1001 Has Additive HbF-Inducing Activity in Combination with Hydroxyurea and Decitabine.

Susan Perrine, MD, Douglas V. Faller, MD, PhD, Ling Shen, MD, MPH, Michael Boosalis, PhD, Gary White, DVM, Hua Cao, MD, PhD, Ray Fei, MD, Audry Thomson, MS, Ronald Berenson, MD

Blood (2009) 114 (22): 977.

https://doi.org/10.1182/blood.V114.22.977.977

Published: 2009

Journal Articles

Phase 1 Clinical Testing of HQK-1001, a Novel Oral Fetal Globin Gene Inducer

Susan Perrine, MD, William C Welch, PhD, Jeffrey Keefer, MD, PhD, Robin L Downey, MD, Michael S Boosalis, PhD, Sally Case, RN, Douglas V Faller, MD, PhD, Ronald Berenson, MD

Blood (2008) 112 (11): 130.

https://doi.org/10.1182/blood.V112.11.130.130

Published: 2008

Journal Articles

EKLF Is Recruited to the γ-Globin Gene Promoter as a Co-Activator and Is Required for γ-Globin Gene Induction by Short-Chain Fatty Acids.

Susan P. Perrine, MD, Rishikesh Mankidy, PhD, Michael S. Boosalis, PhD, James J. Bieker, PhD, Douglas V. Faller, MD, PhD

Blood (2007) 110 (11): 1771.

https://doi.org/10.1182/blood.V110.11.1771.1771

Published: 2007

Journal Articles

Telomere-Based Pre-Clinical Therapy in a Murine Model of Non-Hodgkin’s Lymphoma of the Diffuse Large B Cell (DLCL)Type.

Harold Longe, MD, Douglas V. Faller, MD, PhD, Gerald V. Denis, PhD

Blood (2005) 106 (11): 607.

https://doi.org/10.1182/blood.V106.11.607.607

Published: 2005

Journal Articles

Mechanisms of γ-Globin Gene Promoter Activation by HBF-Inducing Short Chain Fatty Acid Derivatives.

Rishikesh Mankidy, PhD, Douglas V. Faller, MD, PhD, Michael S. Boosalis, PhD, Regine Bohacek, PhD, Susan P. Perrine, MD

Blood (2005) 106 (11): 826.

https://doi.org/10.1182/blood.V106.11.826.826

Published: 2005

Journal Articles

A Phase I/II Study of Arginine Butyrate and Ganciclovir in Patients with Epstein-Barr Virus-Associated Lymphoid Malignancies.

Susan P. Perrine, MD, Olivier Hermine, MD, Steven J. Mentzer, MD, Trudy N. Small, MD, Steven M. Horwitz, MD, Joyce Fingeroth, MD, Farid Boulad, MD, Massima Di Nicola, MD, Christoph Klein, MD, PhD, Richard O’Reilly, MD, Arthur Levy, MD, Douglas V. Faller, MD, PhD.

Blood (2004) 104 (11): 609.

https://doi.org/10.1182/blood.V104.11.609.609

Published: 2004

NARROW

Oral Nanatinostat (Nstat) and Valganciclovir (VGCV) in Patients with Recurrent Epstein-Barr Virus (EBV)-Positive Lymphomas: Initial Phase 2 Results

Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)

Patient-Centered Evaluation of Clinical Benefit in Acute Myeloid Leukemia: Importance of Early Engagement with Patients

Assessing Patient-Reported Outcomes in People with Myelodysplastic Syndromes: Can a Customized Selection of Items from the EORTC Library Enhance the EORTC QLQ-C30?

Patient Perspectives on Symptom Experience and Impact on Health-Related Quality of Life in Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia

Healthcare Costs in Elderly Patients with Acute Myeloid Leukemia (AML) in Routine Clinical Care in the United States (US)

Enhancing the Content of the EORTC QLQ-C30 to Maximize the Detection of Treatment Benefit in Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myeloid Leukemia Using the EORTC Item Bank

Treatment Characteristics and Outcomes for Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia (AML) Treated in the United States with Either 7+3 or a Hypomethylating Agent (HMA)

Multiple Oral Therapeutics Suppress Repressors (LSD-1, HDACs, and BCL11A) of Gamma Globin Gene Expression

Next Generation Clinical-Stage HbF Inducers Exhibit Multiple Molecular Actions In Vitro and In Vivo and Offer Personalized Therapeutic Regimens

An Approach for Tailoring Diverse Therapeutic Inducers of Fetal Globin to Genetic Modifier Profiles,

Identification of New and Diverse Inducers of Fetal Hemoglobin with High Throughput Screening (HTS)

Short-Term Exposure to Arginine Butyrate, in Combination with Ganciclovir, Is as Effective as Continuous Exposure for Virus-Targeted Therapy of EBV-Positive Lymphomas.

HQK-1001 Has Additive HbF-Inducing Activity in Combination with Hydroxyurea and Decitabine.

Phase 1 Clinical Testing of HQK-1001, a Novel Oral Fetal Globin Gene Inducer

EKLF Is Recruited to the γ-Globin Gene Promoter as a Co-Activator and Is Required for γ-Globin Gene Induction by Short-Chain Fatty Acids.

Telomere-Based Pre-Clinical Therapy in a Murine Model of Non-Hodgkin’s Lymphoma of the Diffuse Large B Cell (DLCL)Type.

Mechanisms of γ-Globin Gene Promoter Activation by HBF-Inducing Short Chain Fatty Acid Derivatives.

A Phase I/II Study of Arginine Butyrate and Ganciclovir in Patients with Epstein-Barr Virus-Associated Lymphoid Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only